Heart failure (HF) and pulmonary hypertension (PH) are increasingly prevalent comorbidities in patients presenting for noncardiac surgery. The unique pathophysiology and pharmacotherapies associated with these syndromes have important perioperative implications. As new medications for HF and PH emerge, it is imperative that anesthesiologists and other perioperative providers understand their mechanisms of action, pharmacokinetics, and potential adverse effects. We present an overview of the novel HF and PH pharmacotherapies and strategies for their perioperative management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.anclin.2023.09.004 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!